This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Palmidrol
- DrugBank Accession Number
- DB14043
- Background
A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).
- Type
- Small Molecule
- Groups
- Experimental, Nutraceutical
- Structure
Structure for Palmidrol (DB14043)
- Weight
- Average: 299.4919
Monoisotopic: 299.282429433 - Chemical Formula
- C18H37NO2
- Synonyms
- Hydroxyethylpalmitamide
- Monoethanolamine palmitic acid amide
- N-(2-Hydroxyethyl)palmitamide
- N-hexadecanoylethanolamine
- N-palmitoylethanolamine
- Palmidrol
- palmidrolum
- Palmitamide MEA
- Palmitic acid monoethanolamide
- Palmitinsaeure-beta-hydroxyethylamid
- Palmitoyl ethanolamide
- Palmitoyl-EA
- Palmitoylethanolamide
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Palmidrol is combined with 1,2-Benzodiazepine. Acebutolol The risk or severity of Tachycardia can be increased when Palmidrol is combined with Acebutolol. Acetazolamide The risk or severity of adverse effects can be increased when Palmidrol is combined with Acetazolamide. Acetophenazine The risk or severity of adverse effects can be increased when Palmidrol is combined with Acetophenazine. Aclidinium The risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with Palmidrol. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Palmidrol. Agomelatine The risk or severity of adverse effects can be increased when Palmidrol is combined with Agomelatine. Alfentanil The risk or severity of adverse effects can be increased when Palmidrol is combined with Alfentanil. Alimemazine The risk or severity of adverse effects can be increased when Palmidrol is combined with Alimemazine. Almotriptan The risk or severity of adverse effects can be increased when Palmidrol is combined with Almotriptan. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Palmdrol prodes
Categories
- Drug Categories
- Agents producing tachycardia
- Alcohols
- Amines
- Amino Alcohols
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Infective Agents
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cannabinoids and similars
- Central Nervous System Agents
- Fatty Acids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Lipids
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as carboximidic acids. These are organic acids with the general formula RC(=N)-OH (R=H, organic group).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboximidic acids and derivatives
- Sub Class
- Carboximidic acids
- Direct Parent
- Carboximidic acids
- Alternative Parents
- Propargyl-type 1,3-dipolar organic compounds / Alkanolamines / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic acyclic compound / Alkanolamine / Carboximidic acid / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- N-(long-chain-acyl)ethanolamine, endocannabinoid, N-(saturated fatty acyl)ethanolamine (CHEBI:71464) / N-acyl ethanolamines (endocannabinoids) (LMFA08040013)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6R8T1UDM3V
- CAS number
- 544-31-0
- InChI Key
- HXYVTAGFYLMHSO-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
- IUPAC Name
- N-(2-hydroxyethyl)hexadecanamide
- SMILES
- CCCCCCCCCCCCCCCC(=O)NCCO
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0002100
- KEGG Drug
- D08328
- KEGG Compound
- C16512
- ChemSpider
- 4509
- BindingDB
- 29083
- 2001986
- ChEBI
- 71464
- ChEMBL
- CHEMBL417675
- ZINC
- ZINC000008035017
- Wikipedia
- Palmitoylethanolamide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Pain, Chronic 1 3 Recruiting Treatment Migraine 1 2 Completed Treatment Gilles de la Tourette's Syndrome 1 2 Recruiting Treatment Chemotherapy Induced Peripheral Neuropathy (CIPN) / Hematopoietic and Lymphoid Cell Neoplasm / Malignant Solid Neoplasms 1 2 Recruiting Treatment Fibula Fracture / Knee Fracture / Tibial Fractures 1 2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1 2 Unknown Status Treatment Gilles de la Tourette's Syndrome 1 2, 3 Completed Treatment Atopic Dermatitis 1 0 Not Yet Recruiting Treatment Opioid Use Disorder (OUD) 1 Not Available Completed Basic Science Amyotrophic Lateral Sclerosis (ALS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00136 mg/mL ALOGPS logP 5.74 ALOGPS logP 4.98 Chemaxon logS -5.3 ALOGPS pKa (Strongest Acidic) 15.46 Chemaxon pKa (Strongest Basic) -1.3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 49.33 Å2 Chemaxon Rotatable Bond Count 16 Chemaxon Refractivity 90.09 m3·mol-1 Chemaxon Polarizability 40.05 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0w29-7179000000-22766d934944105dccf9 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-03dl-9130000000-c6d2bfc2e68da1f5b0d2 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01ox-9410000000-d078025cabaaf62c59b9 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-1090000000-5224a67dd0daaea79191 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-01ot-5090000000-dd9396934201d60f5af2 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9010000000-d5bf936e945bfc965dfe
Drug created at May 22, 2018 17:59 / Updated at February 21, 2021 18:54